- Home
- GLTO vs VRPX Comparison
GLTO vs VRPX Comparison
Compare GLTO & VRPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- VRPX
- Stock Information
- Founded
- GLTO 2011
- VRPX 2016
- Country
- GLTO Denmark
- VRPX United States
- Employees
- GLTO N/A
- VRPX N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- VRPX Medicinal Chemicals and Botanical Products
- Sector
- GLTO Health Care
- VRPX Health Care
- Exchange
- GLTO Nasdaq
- VRPX Nasdaq
- Market Cap
- GLTO 6.5M
- VRPX 6.0M
- IPO Year
- GLTO 2020
- VRPX 2021
- Fundamental
- Price
- GLTO $4.51
- VRPX $0.26
- Analyst Decision
- GLTO Buy
- VRPX Hold
- Analyst Count
- GLTO 1
- VRPX 1
- Target Price
- GLTO $10.00
- VRPX N/A
- AVG Volume (30 Days)
- GLTO 14.7K
- VRPX 8.8M
- Earning Date
- GLTO 03-07-2025
- VRPX 03-25-2025
- Dividend Yield
- GLTO N/A
- VRPX N/A
- EPS Growth
- GLTO N/A
- VRPX N/A
- EPS
- GLTO N/A
- VRPX N/A
- Revenue
- GLTO N/A
- VRPX N/A
- Revenue This Year
- GLTO N/A
- VRPX N/A
- Revenue Next Year
- GLTO N/A
- VRPX N/A
- P/E Ratio
- GLTO N/A
- VRPX N/A
- Revenue Growth
- GLTO N/A
- VRPX N/A
- 52 Week Low
- GLTO $4.24
- VRPX $0.23
- 52 Week High
- GLTO $23.50
- VRPX $5.48
- Technical
- Relative Strength Index (RSI)
- GLTO 39.75
- VRPX 40.47
- Support Level
- GLTO $4.39
- VRPX $0.25
- Resistance Level
- GLTO $4.84
- VRPX $0.47
- Average True Range (ATR)
- GLTO 0.31
- VRPX 0.04
- MACD
- GLTO 0.00
- VRPX 0.00
- Stochastic Oscillator
- GLTO 26.73
- VRPX 4.86
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About VRPX Virpax Pharmaceuticals Inc.
Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.